A polymorphism of the interleukin-1 β gene influences survival in pancreatic cancer by Barber, M D et al.
Despite progress in diagnosis and staging, pancreatic cancer still
has a dismal prognosis (Ahlgren, 1996), however, it remains
difficult to predict survival in patients with advanced pancreatic
cancer. We have previously determined that nutritional and inflam-
matory factors such as albumin and C-reactive protein (CRP) are
of major importance in determining survival (Falconer et al,
1995). This appears to be due to their relationship to the progres-
sive nutritional decline or cachexia seen in the majority of patients
with advanced pancreatic cancer, resulting in increased energy
expenditure, reduced nutritional intake and death due to wasting
(Warren, 1935; Falconer et al, 1994; Wigmore et al, 1997).
However, albumin and CRP are sensitive to clinical events often
experienced by patients around the time of diagnosis, such as jaun-
dice, cholangitis and surgery, and thus they are of limited use in
determining palliative therapy for these patients.
The acute phase protein response, of which the changes in
albumin and CRP concentrations form a part, is modulated by 
pro-inflammatory cytokines. Many pro-inflammatory cytokines,
including interleukin (IL)-1, IL-6, interferon-γ and tumour
necrosis factor (TNF), will give rise to aspects of cachexia when
administered in animal models (Mahony and Tisdale, 1988;
Gelin et al, 1991; Hellerstein et al, 1989; Matthys et al, 1991;
Strassmann et al, 1992). Although production of these cytokines
depends on a variety of clinical factors, there is increasing
evidence that genetic factors may be involved. Variations in
the genes coding for IL-1 and TNF have been found to affect
production of the relevant cytokines (Pociot et al, 1992; Stüber
et al, 1996). If these polymorphisms were relevant to the survival
of patients they would offer a window on the inflammatory state of
the patient independent of their clinical condition and therefore
may be useful in guiding palliative intervention. We have
previously shown that two polymorphisms of the TNF gene do
not influence the inflammatory state or survival in advanced
pancreatic cancer (Barber et al, 1999).
This study examined a bi-allelic TaqI polymorphism of the
IL-1β gene (13) in patients with advanced pancreatic cancer and
related this to IL-1β production, CRP concentration and survival.
METHODS
Subjects
After informed consent, venous blood was collected for IL-1β
genotyping from 64 consecutive patients with a diagnosis of
unresectable pancreatic cancer based on histological or un-
equivocal radiological or operative findings. In order to assess the
inflammatory state it was felt to be important to collect samples
from patients without evidence of infection or jaundice approxi-
mately one month after diagnosis, surgery or endobiliary stenting.
It was possible to obtain venous blood from 43 such patients
for the measurement of serum CRP and 22 such patients for
measurement of peripheral blood mononuclear cell (PBMC) IL-1β
production.
Blood was also collected for IL-1β genotyping from 101
healthy volunteers from the same geographical area attending
the Blood Transfusion Service Plasmapheresis Centre in
Edinburgh.
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Survival was noted from time of histological confirmation of
pancreatic adenocarcinoma (80%) or of unequivocal radiological
or operative findings in those for whom histological confirmation
was not obtained. Approval for the study was obtained from the
Lothian Ethical Committee.
IL-1β genotyping
DNA was extracted from 1 ml samples of EDTA anticoagulated
blood using a Puregene DNA isolation kit based on a simple
salting out technique (Miller et al, 1988) (Gentra systems, North
Carolina, USA). The polymerase chain reaction (PCR) was used to
amplify a 699 bp fragment of the IL-1β genomic sequence using
primers upstream 5′ TGT TCT TAG CCA CCC CAC TC 3′ and
downstream 5′ ATC GCT CCA GCA CTC TTG TT 3′ (Genosys,
Pampisford, UK) designed on the basis of the published sequence
(Clark et al, 1986) using the Primer 3 program (Rozen and
Skaletsky, 1996). The following PCR protocol was used – 3 cycles
of 97° C for 1.5 minutes, 54° C for 1.5 minutes, 74° C for 1 minute;
32 cycles of 97° C for 0.5 minutes, 54° C for 0.5 minutes, 74° C for
1.5 minutes; and 72° C for 10 minutes using reagents supplied by
Promega (Southampton, UK) on a Hybaid Omn-E thermal cycler
(Teddington, UK). The PCR product was digested directly with 0.5
µ of TaqI restriction enzyme (Appligene, Chester-le-Street, UK) at
65° C for 4 hours. Restriction enzyme products were analysed on
1% NuSieve agarose (FMC bioproducts, Rockland, Maine, USA)
or 6% polyacrylamide gels (Biorad, Hemel Hempstead, UK). The
cleaved product produced bands at 524 and 175 bp representing
allele 1 while the uncleaved 699 bp product represented allele 2
(Figure 1).
Cytokine production
Serum IL-1β levels were measured by ELISA (Quantikine High
Sensitivity, R & D System, Abingdon, UK). Limit of detection was
0.2 pg ml–1.
PBMCs were separated from 20 ml of heparin anticoagulated
blood on a hypaque gradient (Histopaque 1077, Sigma, Poole,
UK) by centrifuging at 1500 rpm for 30 minutes. Cells from the
interface were removed and washed three times in cell culture
medium (Roswell Park Memorial Institute medium 1640, Life
Technologies, Paisley, UK) with penicillin, streptomycin and glut-
amine (2 mmol l–1) (Sigma) added. Cells were resuspended,
counted and cultured in 96-well, flat-bottomed tissue culture plates
(Corning Coster, High Wycombe, UK) at a concentration of 2 ×
105 per well in 200 µ l cell culture medium with 10% fetal calf
serum in the presence of 10 µ g ml–1 E. coli lipopolysaccharide
(Sigma). Supernatants from PBMC cultures were removed at 24
hours and stored at –70° C for subsequent analysis. IL-1β content
of supernatants was measured by ELISA (Quantikine, R & D
Systems, Abingdon, UK). Limit of detection was 4 pg ml–1.
Serum CRP levels were measured by an automated immuno-
turbidometric method (Abbott Laboratories, Maidenhead, UK).
Limit of detection was 10 mg l–1.
Statistical analysis
Data are presented as median and interquartile range unless other-
wise stated. Comparisons between groups of continuous variables
were made by the Mann-Whitney U test. Categorical variables
were compared by the Chi-squared test. Correlation between
continuous variables were assessed by the Spearman rank correla-
tion coefficient. Survival was analysed using the Kaplan-Meier
technique and groups compared by the log rank test. A P value of
less than 0.05 was taken to denote significance.
RESULTS
Subject characteristics and prevalence of IL-1β genotypes are
presented in Table 1. 30 patients had UICC stage II disease,
8 patients stage III and 26 patients stage IV. No subject underwent
resectional surgery or received chemotherapy or radiotherapy.
There was no significant difference in the distribution of
genotypes between pancreatic cancer patients and healthy
controls.
IL-1β was only detectable in serum from two patients (without
infection or jaundice). One patient of genotype 2/2 had a serum
level of 7.24 pg ml–1 while a patient of 1/2 genotype had a level of
1.16 pg ml–1. Both patients had substantially elevated serum CRP
levels at 151 and 53 mg l–1 respectively.
IL-1β production by PBMCs from cancer patients (without
evidence of infection or jaundice, approximately 1 month after
diagnosis, surgery or endobiliary stenting) by IL-1β genotype is
presented in Figure 2. PBMC IL-1β production by those with a
2/2 genotype (median 9.7 ng ml–1 (range 7.9–11.5)) was signifi-
cantly higher than those with 1/2 (2.2 (interquartile range 1.5–2.7),
P = 0.046) or 1/1 (1.9 (1.4–2.6), P = 0.027) genotype. There was
no significant difference between PBMC IL-1β production
between 1/2 and 1/1 genotype (P = 0.72). There was no significant
relationship between PBMC IL-1β production and CRP level
(r = 0.28, P = 0.21).
Serum CRP level by IL-1β genotype of cancer patients (without
evidence of infection or jaundice, approximately 1 month after
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Figure 1 6% polyacrylamide gel showing interleukin-1β genotyping. 699 bp
fragment of IL-1β gene has been amplified by PCR and digested with TaqI
restriction enzyme. Allele 1 is cleaved into 175 and 524 bp fragments while
allele 2 remains uncleaved at 699 bp
Table 1 Characteristics of patients with advanced pancreatic cancer and
healthy controls
Interleukin-1β genotypea
Age Sex 1/1 1/2 2/2
Cancer patients (n = 64) 64 30F 68% 25% 6%
(57–72) 34 M
Healthy controls (n = 101) 42 32F 55% 40% 5%
(36–47) 69 M
M: male, F: female. aComparison between groups by Chi squared 
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diagnosis, surgery or endobiliary stenting) is presented in Figure 3.
CRP levels from those with the 2/2 (28 mg l–1 (20–130)) or 1/2
genotype (31 mg l–1 (13–72)) were significantly higher than those
with the 1/1 genotype (0 mg l–1 (0–10)) (P = 0.015 and 0.0042,
respectively). There was no significant difference between CRP
levels from those with 2/2 and 1/2 genotypes (P = 0.42).
Survival of patients by IL-1β genotype is presented in Figure 4.
Those with 2/2 genotype (88 days (69–108)) had significantly
shorter survival than those with 1/2 (173 days (107–269)) or 1/1
(243 days (126–333)) genotype (P = 0.012 and 0.0001 respec-
tively). The difference between survival of those with 1/1 and 1/2
genotype is not quite significant (P = 0.10). All 4 censored indi-
viduals possess the 1/1 genotype. Those possessing allele 2 had
significantly shorter survival (148 days (85–245)) than those who
did not (243 days (126–333)) (P = 0.043) (Figure 5).
Disease stage was not a significant predictor of survival in this
group of patients (P = 0.65). When survival by IL-1β genotype
was split by disease stage genotype remained a significant
predictor of survival in those with stage II and IV disease where
sufficient numbers were available for analysis (P = 0.025 and
P = 0.028, respectively).
For predicting survival at 6 months the possession of allele 2 has
a sensitivity of 48%, a specificity of 81%, a positive predictive
value of 65%, a negative predictive value of 67% and an accuracy
of 67%.
DISCUSSION
In this study of patients with advanced pancreatic cancer we have
shown that IL-1β genotype appears to be important in determin-
ing IL-1β production, serum CRP level and survival from
diagnosis.
There was no difference in the distribution of genotypes
between normal subjects and cancer patients. The distribution
found in normal subjects is very similar to that described in other
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Figure 2 Interleukin-1β production by peripheral blood mononuclear cells
from 22 patients with advanced pancreatic cancer without infection or
jaundice measured approximately 4 weeks after diagnosis, surgery or
endobiliary stenting presented by IL-1β genotype (1/1 – 14 patients,
1/2 – 6 patients, 2/2 – 2 patients). Horizontal bar represents median value.
Comparisons between groups by Mann-Whitney U test.
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Figure 3 Serum C-reactive protein levels from 43 patients with advanced
pancreatic cancer without infection or jaundice measured approximately
4 weeks after diagnosis, surgery or endobiliary stenting presented by IL-1β
genotype (1/1 – 28 patients, 1/2 – 12 patients, 2/2 – 3 patients). Horizontal
bar represents median value. Comparisons between groups by Mann-
Whitney U test.
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Figure 4 Kaplan-Meier plot of survival of 64 patients with advanced
pancreatic cancer presented by IL-1β genotype. Median survivals –
1/1 genotype 243 days (solid line), 1/2 173 days (broken line), 2/2 88 days
(dotted line). Comparison by log rank test – overall P = 0.0005, 
1/1 vs 1/2 P = 0.010, 1/1 vs 2/2 P = 0.0001, 1/2 vs 2/2 P = 0.012.
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Figure 5 Kaplan-Meier plot of survival of 64 patients with advanced
pancreatic cancer stratified for possession of IL-1β allele 2. Median
survivals – possession of allele 2–148 days (broken line), no allele
2–243 days (solid line). Comparison by log rank test – P = 0.043.1446 MD Barber et al
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European populations (Pociot et al, 1992; Bioque et al, 1995;
Heresbach et al, 1997). There was a trend towards fewer cancer
patients possessing allele 2. If possession of allele 2 shortens
survival we may have missed some patients who died before
assessment, thus our estimate of the importance of allele 2 may be
a conservative one.
It is rare to detect IL-1 in the serum of cancer patients, thus
measures of production are more important for gauging in vivo
levels (Moldawer and Copeland, 1997). Only one group has previ-
ously studied the relationship between this IL-1β polymorphism
and production of IL-1β by leukocytes (Pociot et al, 1992).
Examining a group of 45 healthy individuals they were able to
show a stepwise increase in IL-1β production from 1/1 to 1/2 to
2/2 genotype. While numbers in the present study were insuffi-
cient to confirm this relationship, differences between the 2/2
genotype and the other groups were significant and there was a
marked trend in agreement with this previous study (P = 0.072 –
Kruskal-Wallis test).
The relationship between IL-1β genotype and the acute phase
protein response has not previously been examined. It is known
that the administration of IL-1α or β will induce an acute phase
response in mice (Moldawer et al, 1988) and that the administra-
tion of antibodies to the IL-1 receptor will attenuate the acute
phase response to turpentine abscess in mice (Gerschenwald et al,
1990). It is thought that the acute phase response is primarily acti-
vated by IL-6 (Castell et al, 1990) but it has been suggested that
blockade of IL-1 action will reduce IL-6 production (Yasumoto
et al, 1995). In the present study we failed to identify any simple
relationship between serum CRP levels and IL-1β production
although IL-1β genotype again seemed to be important with those
possessing allele 2 having significantly higher CRP levels than
those without.
The administration of pro-inflammatory cytokines, including
IL-1, IL-6, interferon-α and TNF, produces features of cachexia in
experimental models (Mahony and Tisdale, 1988; Hellerstein et al,
1989; Gelin et al, 1991; Matthys et al, 1991; Strassmann et al,
1992). These agents all induce an acute phase response and it has
been suggested that the need for amino acids to manufacture acute
phase reactants in the absence of adequate nutritional intake
contributes to breakdown of skeletal muscle and so the weight loss
of cachexia (Reeds et al, 1994). We have previously shown that the
presence of an acute phase response is associated with nutritional
decline and poor survival in pancreatic cancer (Falconer et al,
1994, 1995; Wigmore et al, 1997). In this study we have shown
that IL-1β genotype is related to survival. The stepwise decrease in
median survival between the 1/1, 1/2 and 2/2 genotypes would
appear to correspond with the apparent increase in IL-1β produc-
tion and would therefore be compatible with the hypothesis that a
more marked pro-inflammatory state is detrimental to survival in
pancreatic cancer, perhaps due to nutritional decline. It has also
been suggested that pro-inflammatory cytokines will promote
tumour growth in animal models (Gelin et al, 1991). Blockade of
the IL-1 receptor has been shown to reduce liver metastasis in a
melanoma model (Vidal-Vanaclocha et al, 1994) perhaps due to
an IL-1 induced increase in endothelial receptor expression
(Vidal-Vanaclocha et al, 1996).
The very poor survival of patients with 2/2 genotype is of
limited value clinically due to the low prevalence of this genotype,
however, the possession of allele 2 was also a significant predictor
of survival. This was present in a third of the cancer patients in the
present study and almost a half of the population as a whole so it
may be a valuable clinical tool for predicting survival. It has been
suggested that endoscopic palliation of jaundice rather than
surgical biliary bypass is appropriate in those patients with a life
expectancy of 6 months or less (van den Bosch et al, 1994;
Rosewicz and Weidenmann, 1997). Existing measures of the
inflammatory state are sensitive to surgery, infection and jaundice
while IL-1β genotype is not. Using this method to predict 6-month
survival had an accuracy of 67% in the current study suggesting
that it may be useful in guiding palliative biliary drainage in these
patients.
In conclusion, IL-1β genotype is related to IL-1β production
and the level of the acute phase protein response and affects
survival in patients with advanced pancreatic cancer.
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